Absci (ABSI) Stock Price, News & Analysis

Company Overview

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Key Stats

• Today's Range: $4.79 to $5.41
• 50-Day Range: $2.62 to $5.82
• 52-Week Range: $2.45 to $6.72
• Volume: 4.94 million shs
• Average Volume: 7.00 million shs
• Market Capitalization: $569.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.57
• Consensus Rating: Buy

Absci Stock Analysis - MarketRank™

Absci scored higher than 57% of companies evaluated by MarketBeat, and ranked 451st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Absci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Absci has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Absci are expected to grow in the coming year, from ($0.89) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Absci is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Absci is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Absci has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

20.63% of the float of Absci has been sold short.

Short Interest Ratio / Days to Cover

Absci has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Absci has recently decreased by 10.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Absci does not currently pay a dividend.

Dividend Growth

Absci does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

20.63% of the float of Absci has been sold short.

Short Interest Ratio / Days to Cover

Absci has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Absci has recently decreased by 10.78%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.86

News Sentiment

Absci has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Absci this week, compared to 3 articles on an average week.

Search Interest

19 people have searched for ABSI on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.

MarketBeat Follows

24 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Absci insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.81% of the stock of Absci is held by insiders.

Percentage Held by Institutions

52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABSI Stock Analysis - Frequently Asked Questions

How have ABSI shares performed this year?

Absci's stock was trading at $2.62 on January 1st, 2025. Since then, ABSI stock has increased by 89.1% and is now trading at $4.9550.
View the best growth stocks for 2025 here.

How were Absci's earnings last quarter?

Absci Co. (NASDAQ:ABSI) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The firm earned $1.70 million during the quarter, compared to analyst estimates of $1.77 million. Absci had a negative net margin of 2,321.56% and a negative trailing twelve-month return on equity of 46.56%.

When did Absci IPO?

Absci (ABSI) raised $200 million in an initial public offering on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share.

Who are Absci's major shareholders?

Absci's top institutional shareholders include ARK Investment Management LLC (7.20%), Fred Alger Management LLC (5.66%), Ameriprise Financial Inc. (2.26%) and Geode Capital Management LLC (1.70%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Redmile Group, Llc and Zachariah Jonasson.
View institutional ownership trends.

How do I buy shares of Absci?

Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Absci own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ABSI
• CUSIP: N/A
• CIK: 1672688
• Web: www.absci.com
• Phone: 360-949-1041
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.57
• High Stock Price Target: $13.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +73.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-110,570,000.00
• Net Margins: -2,321.56%
• Pretax Margin: -2,319.25%
• Return on Equity: -46.56%
• Return on Assets: -39.74%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.63
• Quick Ratio: 5.63

Sales & Book Value

• Annual Sales: $5.72 million
• Price / Sales: 99.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.90 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 114,860,000
• Free Float: 103,589,000
• Market Cap: $569.13 million
• Optionable: Optionable
• Beta: 2.11